Opinion|Videos|January 13, 2025
The Role of Posttransplant Cyclophosphamide in Patients With cGVHD
Author(s)Sergio A. Giralt, MD
Sergio A. Giralt, MD, discusses how he uses cyclophosphamide to treat patients with chronic graft-vs-host disease (cGVHD), particularly in specific cases where other therapies may not be effective. He reviews the study design and methods of recent research investigating cyclophosphamide in cGVHD management, emphasizing its importance in optimizing treatment strategies.
Advertisement
Video content above is prompted by the following:
- Which patients with chronic graft-vs-host disease (cGVHD) do you treat with cyclophosphamide in your clinical practice?
- What were this abstract’s study design and methods, and why was it important to investigate for cGVHD management?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Articles
BCMA-Targeted Bispecific Antibodies: Navigating the New Frontier of MyelomaSeptember 17th 2025
- Linvoseltamab: A New Horizon for Relapsed Myeloma
September 17th 2025
Rapid Therapeutic Effects Seen With a JAK InhibitorSeptember 17th 2025
- SALT Scoring for Alopecia Areata
September 17th 2025
The Potential Role of Screening for Atrial FibrillationSeptember 16th 2025
- Remote Patient Monitoring and Artificial Intelligence
September 16th 2025
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Cumulative Atropine Not Associated With Increased Risk of Ocular Events in Children With Myopia
2
West Coast Health Alliance Releases First Vaccine Guidelines, Aiming to Replace CDC Recommendations
3
Hospitals in Underserved Communities Less Likely to Adopt Health Information Technology
4
Sotatercept Shows Right Heart Gains in PAH: Anjali Vaidya, MD
5
